After Falling 21% in a Month, Is There Any Hope for BioCryst Pharmaceuticals?

[cafead]

via

• Some of its clinical trials have recently paused enrollment.
• Pauses are not uncommon, but they can still rattle shareholders.
• Current medicines on the market are likely to deliver revenue growth for a while.

article source